34 results about "Variant virus" patented technology

The invention relates to the technical field of porcine pseudorabies viruses (PRVs) and in particular relates to a porcine PRV variant PRV-ZJ01 with collection number of CGMCCNo.8170 and an application of the porcine PRV variant PRV-ZJ01 in preparation of vaccines. The porcine PRV variant PRV-ZJ01 has the beneficial effects that a water-soluble inactivated vaccine is prepared by adopting a PRV-ZJ01 variant virus solution and is subjected to a swine immune protection test with live vaccines of Bartha-K61, Bucharest and HB-98 strains and the results show that the inactivated vaccine of the ZJ01 strain has relatively high safety and has the immune protection efficiency obviously higher than that of immunity groups of the live vaccines of the Bartha-K61, Bucharest and HB-98 strains, and the live vaccines of the Bartha-K61, Bucharest and HB-98 strains can not provide full protection for the ZJ01 very virulent strain; the inactivated vaccine of ZJ01 has relatively good immune protection effects on the PRV variant and the traditional strains; infected with 10<6.0>TCID50 (Tissue culture infectious dose 50) / ml nasal drops of the PRV-ZJ01 variant, all the 85-day-old non-immune swine can become ill and die; results prove that the virulence of the virus strain is obviously enhanced, the antigenicity is varied and the virus strain has relatively good immunogenicity after being inactivated and can be used for research and development of the vaccine of the virus strain and the diagnostic methods.

The invention relates to a nucleoside compound and application thereof, in particular to a compound shown in a formula I, a prodrug thereof and / or pharmaceutically acceptable salt thereof, and a preparation method, a composition and application thereof. The compound and the composition have the application of preventing, relieving and / or treating coronavirus infection, or replication or reproduction of homologous variant viruses of the coronavirus infection, and cytopathic effects generated by the coronavirus infection or the replication or reproduction of the homologous variant viruses of the coronavirus infection.

The present invention provides a mNGS-based method for detecting COVID‑19 novel coronavirus and its application. In the method, multiple genome-specific reverse transcription primer sets for COVID‑19 novel coronavirus are designed and prepared to improve the detection of novel coronavirus RNA. Reverse transcription efficiency reduces the problem of aerosol pollution, and also improves the ability to enrich nucleic acid sequences of different mutant viruses.

The invention relates to a Japanese encephalitis virus non-structural protein NS1 truncated mutant, its coding gene and application, and belongs to the technical field of viruses. The non-structural protein NS1 truncation mutant of Japanese encephalitis virus deletes two strong hydrophobic regions at the C-terminus on the basis of the original NS1, and obtains a truncation mutant NS1 with 63 amino acids at the C-terminus deleted △63 Gene, cloned into the prokaryotic expression vector pET‑28a(+), and obtained the recombinant expression vector pET28a‑NS1 △63 , transformed into E. coli, induced by IPTG, NS1 △63 It can be expressed efficiently and stably in Escherichia coli. NS1 expressed in E. coli △63 After protein purification and immunization of mice, the titer of NS1 antiserum of immunized mice reached 1:12150 by ELISA. Protection tests in immunized mice showed that NS1 △63 Has protective activity. The NS1 △63 The protein can lay the foundation for the development of later virus vaccines and diagnostic kits.

A monoclonal antibody against mutant hepatitis B virus surface antigen secreted by hybridoma cell line CGMCC HBSP2. The anti-mutated hepatitis B surface antigen monoclonal antibody prepared according to the present invention can simultaneously detect hepatitis B viruses including 14 kinds of mutant strains and wild strains, and can replace the HBsAb in the conventional hepatitis B surface antigen detection kit. Into the hepatitis B surface antigen diagnostic kit. The use of the antibody can avoid the missed diagnosis caused by conventional reagents, so that the carriers of the mutated and non-mutated hepatitis B virus or hepatitis B patients can be diagnosed and treated in time. Especially when screening blood donors, it can detect mutant virus carriers that cannot be detected by conventional kits, avoid transfusing the blood of hepatitis B patients as healthy blood to recipients, and ensure the quality of blood sources.